CG Oncology director Post sells 1,000 shares

The two 500-share sales were made under a Rule 10b5-1 trading plan adopted on March 5, 2026.

Rhea-AI Filing Summary

Leonard E. Post, a director of CG Oncology, Inc., exercised options covering 1,000 common shares at an exercise price of $0.60 per share on October 15, 2026. On the same date, he sold two blocks of 500 shares at weighted average prices of $61.65 and $62.48 per share. The sales were made under a Rule 10b5-1 trading plan adopted March 5, 2026. His reported post-exercise director stock option position was 102,077 shares.

Insider Trade Summary 10b5-1

Exercise and Sale: 1,000 shares ($61K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider POST LEONARD E

Role Director

Sold 1,000 shs ($62K)

Approx. gross sale proceeds $62K

Approx. exercise cost $600.00

Approx. pre-tax spread $61K

Type	Security	Shares	Price	Value
Exercise	Director Stock Option (right to buy) F4	1,000	$0.00	$0.00
Exercise	Common Stock	1,000	$0.60	$600.00
Sale	Common Stock F1, F2	500	$61.65	$31K
Sale	Common Stock F1, F3	500	$62.48	$31K

Holdings After Transaction: Director Stock Option (right to buy) — 102,077 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (4)

1. F1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.16 to $62.06 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.27 to $62.60 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
4. F4. Fully vested

Key Figures

Shares covered by options exercised: 1,000 common shares Exercise price: $0.60 per share First sale: 500 shares at a $61.65 weighted average price per share +3 more

6 metrics

Shares covered by options exercised 1,000 common shares October 15, 2026

Exercise price $0.60 per share Options exercised on October 15, 2026

First sale 500 shares at a $61.65 weighted average price per share October 15, 2026

Second sale 500 shares at a $62.48 weighted average price per share October 15, 2026

Post-exercise director stock option position 102,077 shares Reported following the October 15, 2026 exercise

Director stock option expiration July 8, 2028 Expiration date stated for the reported option

Key Terms

Rule 10b5-1 trading plan, weighted average price, Director Stock Option

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Director Stock Option financial

"Director Stock Option (right to buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CGON shares did Leonard E. Post sell and at what prices?

Leonard E. Post sold 500 shares at a weighted average price of $61.65 per share and another 500 shares at a weighted average price of $62.48 per share on October 15, 2026. Both sales were made under a Rule 10b5-1 trading plan adopted March 5, 2026.

What price ranges applied to Leonard E. Post's CGON share sales?

The 500 shares reported at a weighted average price of $61.65 were sold in multiple transactions at prices from $61.16 to $62.06, inclusive. The other 500 shares, reported at a weighted average price of $62.48, were sold from $62.27 to $62.60, inclusive.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/19/2026 - 04:30 PM EDT Accepted by SEC EDGAR 10/19/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

POST LEONARD E

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

3000 PEGASUS PARK DRIVE, SUITE 1640

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/15/2026		M		1,000	A	$0.6	1,000	D
Common Stock	10/15/2026		S(1)		500	D	$61.65(2)	500	D
Common Stock	10/15/2026		S(1)		500	D	$62.48(3)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$0.6	10/15/2026		M			1,000	(4)	07/08/2028	Common Stock	1,000	$0	102,077	D

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.16 to $62.06 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.27 to $62.60 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. Fully vested

	/s/ Joshua F. Patterson, Attorney-in-Fact for Leonard Post	10/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)